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WS19.1 Using microsystems methods to improve nutritional
outcomes in an adult CF center: a quality improvement (QI)
initiative
M. Ferrin1, M. Nicolo1, D. Dorgan1, D. Hadjiliadis1, D. Holsclaw1,
M. Shechtman1, P. Kreider2, C.B. Robinson1. 1University of Pennsylvania,
Pulmonary and Critical Care, Philadelphia, United States; 2Patient, Philadelphia,
United States
Objectives: A global aim was to become one of the top 10 best performing centers
in the US based on pulmonary and nutritional data; our speciﬁc aim is to reduce the
percentage of patients at nutritional risk not seen by our registered dietician (RD)
by 10% over a 3 month period (quarter #3, 2011). We chose this project because,
based on our center speciﬁc data from the CF Foundation registry, at our program
the percentage of patients at nutritional risk seen by a dietician (58%) was well
below the national average (82%).
Methods: We assembled an interdisciplinary core team consisting of dietician,
social worker, physicians, and nurse practitioner; a 5-member patient advisory board
was recruited to identify patients’ priorities for improvement. We used the Plan-Do-
Study-Act (PDSA) approach. PDSA #1: examination of our clinic ﬂow, to identify
any inefﬁciencies. Flow started with our Monday team meeting, and ended with
our after-clinic wrap-up. Our Monday meeting was used to target patients for RD
to see that week. Over a 3-month period we were able to identify and intervene for
those patients needing dietician expertise.
Conclusions: Our data reﬂected a signiﬁcant improvement: in quarter3, 2011
(30%) compared to the annual data from 2009(58%). Lessons learned included
standardizing the way in which heights and weights are recorded; focusing our team
meeting; implementing changes in clinic ﬂow (process). These lessons are included
as standard procedures (“playbook”). PDSA #2: survey of patients to identify their
priorities for our process. PDSA#2 data are pending. Lesson learned: patients are
eager to participate in our program QI.
Supported by CFF AQI2.
WS19.2 Development and application of quality improvement
questionnaire in adults with cystic ﬁbrosis
B. Grogan1, K.R. Siklosi1, C.G. Gallagher1, E. McKone1. 1St. Vincent’s University
Hospital, National Referral Center for Adult Cystic Fibrosis, Dublin, Ireland
Background: Understanding quality of care is an important aspect of the manage-
ment of patients with cystic ﬁbrosis. We developed a questionnaire to examine CF
patients’ perceptions of inpatient and outpatients care received in our CF unit.
Methods: Focused interviews with CF patients, their caregivers and members of
the CF team were carried out examining factors that inﬂuence perceived quality
of care. A 30-question questionnaire was developed addressing inpatient and
outpatient experiences, compliance with treatments, CF knowledge and patient
demographics. Questionnaires were then administered prospectively to patients
attending St. Vincent’s University Hospital Adult CF Unit. All questionnaires were
anonymous.
Results: Of 160 CF patients approached to participate, 113 (71%) responded and
completed the questionnaire. Fifty six percent were male, 40% of participants had
FEV1 <40% predicted. Overall 71% were satisﬁed with quality of care with 20%
neither satisﬁed nor dissatisﬁed. Main reasons for dissatisfaction related to issues
with inpatient facilities. Impediment to admission to hospital included concerns
about cross infection (23%), lack of availability of single rooms (18%) and wish
for home IV therapy (22%). The most common reason for missing clinic and annual
review appointments was due to inability to take time off because of work/school
commitments (39%).
Conclusions: Overall, patients expressed satisfaction with perceived quality of care.
Impediments to attending clinic visits and admission to hospital were identiﬁed and
are being addressed as part of ongoing local quality improvement.
WS19.3 Transforming clinics to support adherence: an exercise in
continuous quality improvement
Y. Locke1, S. Harrison2, R. Baines1,2, S. Davies2, J. Boulton2, M. Wildman1.
1Shefﬁeld Teaching Hospitals, Adult CF Unit, Shefﬁeld, United Kingdom; 2Shefﬁeld
Teaching Hospitals, Qulaity Improvement Department, Shefﬁeld, United Kingdom
Background: Continuous quality improvement (CQI) is embedded in the US
approach to CF care [1]. In adopting CQI we aim to move from a rescue based
treatment paradigm to an approach based on prevention by an iterative cycle of
adherence improvement. Much adherence support occurs in the outpatient clinic and
we used CQI to reduce waiting times and maximise patient contact time to provide
an optimum environment for relationship building and adherence interventions.
Method: The Clinical Microsystems approach was employed. The outpatient
process was mapped. Clinic cycle times were measured so that arrival time and
the time to each MDT contact was logged allowing waiting and clinical contact
times to be understood. In keeping with the Microsystems approach when we used
our data on MDT contacts to schedule appointments rather than scheduling around
the median consultation time we planned to the 80th centile. We then used an
iterative plan do study act (pdsa) cycle to identify and eliminate sources of waiting.
Results: Prior to the intervention in May 2011 the mean clinic cycle time was 83
minutes with a waiting time of 40 minutes and clinical contact time of 43 minutes
(52% contact time). After CQI in November 2011 the mean cycle time had reduced
to 59 minutes with a waiting time of 8 minutes and a contact time of 51 minutes
(87% contact time).
Discussion: Frustrated patients are known to be less adherent. Removing most of
the waiting time from clinic has improved patient satisfaction and provided a calm
unhurried environment which enhances relationships and supports adherence. The
techniques of CQI were fundamental in achieving transformation.
Reference(s)
[1] Thorax 2011;66:1106–1108.
WS19.4 CF quality improvement program: a pilot phase to experiment
the US QIP approach in France
G. Rault1, D. Pougheon Bertrand2, L. Gue´ganton3, G. Minguet4, P. Lombrail5.
1CHU Nantes, Nantes-Roscoff CF Expertise Centre, Roscoff, France; 2Dominique
Bertrand Conseil, Rueil-Malmaison, France; 3Centre de Perharidy, Roscoff,
France; 4Ecole Nationale des Mines Nantes, Nantes, France; 5Universite´ Paris
13, Sante´ Publique, Paris, France
Background: The French CF Patients Registry shows variability among patients
outcomes in the 49 CF Centres. Referring to the US QIP, microsystem approach is
experienced to improve quality of CF care in France.
Objectives:
i. Ascertain applicability and effectiveness of clinical microsystem approach for
CF care improvement in France
ii. Adapt the methodology for Teams full ownership.
Methods: QIP organization: national coordination by Nantes Expertise Centre;
selection of 7 CF Pilot Centres (n = 1000 patients out of 5700 in the French registry);
Transparency of outcomes between the Pilot centres; QIP steering committee in
each Pilot Centre including a patient/parent and a “Quality Referent”; Release of a
French QIP Action Guide and a Patient Registry report with 10 goals and advice
to meet them; Set up a web collaborative environment; Support from the US CFF
and The Dartmouth Institute.
One year curriculum: 3 face-to-face meetings, 5 intermediate WEBEX sessions, as
many Team coaching phone meetings as needed, 1 benchmarking visit in a high
performing Centre.
Pilot Phase Evaluation, before the national deployment, carried out by an external
researcher and based on:
i. Key indicators as professionals & patients representatives satisfaction, Teams
participation rate, completion of phases, PDSA cycles achieved
ii. focus group and individual interviews
iii. patients outcomes.
Conclusions: Clinical microsystem approach seems appropriate in France with
some adjustments in the support organization. The part time resource designated
as the “Quality Referent” in each centre is paramount. Data on effectiveness and
patients outcomes (FEV1, BMI) will be available by June 2012.
